title: High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.
abstract: We analyzed the reverse transcriptase genotypes of human immunodeficiency virus type 1 subtype C viruses isolated from 23 patients in Botswana treated with didanosine-based regimens. The K65R mutation was selected either alone or together with the Q151M, S68G, or F116Y substitution in viruses from seven such individuals. The results of in vitro passage experiments were consistent with an apparent increased propensity of subtype C viruses to develop the K65R substitution.
authors.affiliation: Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education, Gaborone, Botswana.
authors.forename: Florence
authors.initials: F
authors.lastname: Doualla-Bell
authors.forename: Ava
authors.initials: A
authors.lastname: Avalos
authors.forename: Bluma
authors.initials: B
authors.lastname: Brenner
authors.forename: Tendani
authors.initials: T
authors.lastname: Gaolathe
authors.forename: Madisa
authors.initials: M
authors.lastname: Mine
authors.forename: Simani
authors.initials: S
authors.lastname: Gaseitsiwe
authors.forename: Maureen
authors.initials: M
authors.lastname: Oliveira
authors.forename: Daniella
authors.initials: D
authors.lastname: Moisi
authors.forename: Ndwapi
authors.initials: N
authors.lastname: Ndwapi
authors.forename: Howard
authors.initials: H
authors.lastname: Moffat
authors.forename: Max
authors.initials: M
authors.lastname: Essex
authors.forename: Mark A
authors.initials: MA
authors.lastname: Wainberg
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D001902:Botswana / Q000453:epidemiology; D016049:Didanosine / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D009154:Mutation; D015995:Prevalence
chemical_list: D019380:Anti-HIV Agents; D016049:Didanosine